Results 71 to 80 of about 5,863 (219)

The Next Disease X‐ H5N6 Avian Influenza's Evolving Threat to Human Health and Chances of Future Global Outbreak: A Narrative Review

Health Science Reports, Volume 8, Issue 11, November 2025.
ABSTRACT Background and Aims H5N6 avian influenza has been a concern that can initiate the next global pandemic (called Disease X). Most infections have been among those in Asia, especially China, since the 2014 first human case. With a fatality rate of 61%, the virus is very deadly, even though the total number of human cases is relatively low.
Shoubeho Sadique Shandhi, Mosiur Rahman, Mohammad Shahriar, Ramisa Anjum   +3 more
wiley   +1 more source

Flagellins as Vaccine Adjuvants and Cancer Immunotherapy: Recent Advances and Future Prospects

Immunology, Volume 176, Issue 3, Page 277-303, November 2025.
The figure depicts the role of flagellin in immune cells. Flagellin interacts with TLR5, resulting in the formation of homodimers and the recruitment of MyD88, which activates the IκB and MAPK signalling pathways. This results in the activation of NF‐κB and AP‐1, producing TNF‐α, IL‐6, IL‐8, and IL‐12.
Asma Talukder, Md. Mijanur Rahman, Md. Sifat Rahi, Dean L. Pountney, Ming Q. Wei   +4 more
wiley   +1 more source

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

PLoS Medicine
BackgroundAdjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the RV144-like HIV vaccine regimen ...
Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, One B Dintwe, Faatima Laher Omar, Jia J Kee, Linda-Gail Bekker, Fatima Laher, Nivashnee Naicker, Ilesh Jani, Nyaradzo M Mgodi, Portia Hunidzarira, Modulakgota Sebe, Maurine D Miner, Laura Polakowski, Shelly Ramirez, Michelle Nebergall, Simbarashe Takuva, Lerato Sikhosana, Jack Heptinstall, Kelly E Seaton, Stephen De Rosa, Carlos A Diazgranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Susan W Barnett, Niranjan Kanesa-Thasan, James G Kublin, Georgia D Tomaras, M Juliana McElrath, Lawrence Corey, Kathryn Mngadi, Paul Goepfert, HVTN 107 Protocol Team   +33 more
doaj   +1 more source

A Self-Emulsified Adjuvant System Containing the Immune Potentiator Alpha Tocopherol Induces Higher Neutralizing Antibody Responses than a Squalene-Only Emulsion When Evaluated with a Recombinant Cytomegalovirus (CMV) Pentamer Antigen in Mice

Pharmaceutics, 2023
The development of new vaccine adjuvants represents a key approach to improvingi the immune responses to recombinant vaccine antigens. Emulsion adjuvants, such as AS03 and MF59, in combination with influenza vaccines, have allowed antigen dose sparing ...
Rushit N. Lodaya, Amey P. Kanitkar, Asma Ashraf, Douty Bamba, Mansoor M. Amiji, Derek T. O’Hagan   +5 more
doaj   +1 more source

Impact of Th1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. [PDF]

, 2020
Generating durable humoral immunity through vaccination depends upon effective interactions of follicular helper T (Tfh) cells with germinal center (GC) B cells.
Amara, Rama R, Beck, Zoltan, Dinasarapu, Ashok R, Elizaldi, Sonny R, Foehl, David H, Forthal, Donald N, Gach, Johannes S, Iyer, Smita S, Kozlowski, Pamela A, LaBranche, Celia C, Lakshmanappa, Yashavanth Shaan, Matyas, Gary R, Nguyen, Nancy K, Rane, Niharika N, Rao, Mangala, Reimann, Keith A, Schmidt, Brian A, Shen, Xiaoying, Tomaras, Georgia D, Trinh, Hung V, Verma, Anil, Walter, Korey A   +21 more
core  

Design Strategies for Novel Lipid Nanoparticle for mRNA Vaccine and Therapeutics: Current Understandings and Future Perspectives

MedComm, Volume 6, Issue 10, October 2025.
This review summarizes strategies to optimize lipid nanoparticles (LNPs) for improved targeting, endosomal escape, and safety. It highlights mRNA design, alternative delivery systems, and recent therapeutic advances across infectious diseases, cancer, and drug applications.
Xiaochi Li, Junli Li, Jiazheng Wei, Weixin Du, Cheng Su, Xiaobin Shen, Aihua Zhao, Miao Xu   +7 more
wiley   +1 more source

Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems

Pharmaceutics, 2022
The SARS-CoV-2 virus has caused a global crisis, resulting in 0.5 billion infections and over 6 million deaths as of March 2022. Fortunately, infection and hospitalization rates were curbed due to the rollout of DNA and mRNA vaccines.
Ahmed O. Shalash, Armira Azuar, Harrison Y. R. Madge, Naphak Modhiran, Alberto A. Amarilla, Benjamin Liang, Alexander A. Khromykh, Waleed M. Hussein, Keith J. Chappell, Daniel Watterson, Paul R. Young, Mariusz Skwarczynski, Istvan Toth   +12 more
doaj   +1 more source

Superior efficacy of a human immunodeficiency virus vaccine combined with antiretroviral prevention in simian-human immunodeficiency virus-challenged nonhuman primates [PDF]

, 2016
International ...
Barnett, Susan W., Cope, Alethea, Dereuddre-Bosquet, Nathalie, Desjardins, Delphine, Dispinseri, Stefania, Gosse, Leslie, Le Grand, Roger, Ochsenbauer, Christina, Prague, Mélanie, Saidi, Hela, Scarlatti, Gabriella, Shattock, Robin J., Shen, Xiaoying, Silvestri, G., Thiébaut, Rodolphe, Tolazzi, Monica, Tomaras, Georgia   +16 more
core   +4 more sources

Vaccination in Multiple Myeloma: Challenges and Strategies

European Journal of Haematology, Volume 115, Issue 4, Page 334-343, October 2025.
ABSTRACT Background Multiple myeloma (MM) is a hematological malignancy characterized by profound immunosuppression resulting from both disease‐related mechanisms and treatment‐induced immune dysfunction. This compromised immune status markedly increases susceptibility to infections, a leading cause of morbidity and mortality in MM patients.
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Santino Caserta, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

A novel CpG ODN compound adjuvant enhances immune response to spike subunit vaccines of porcine epidemic diarrhea virus

Frontiers in Immunology
CpG oligodeoxynucleotides (CpG ODNs) boost the humoral and cellular immune responses to antigens through interaction with Toll-like receptor 9 (TLR9). These CpG ODNs have been extensively utilized in human vaccines. In our study, we evaluated five B-type
Yating Wang, Shijia Liu, Boshuo Li, Xinyao Sun, Qi Pan, Yuxin Zheng, Jia Liu, Yongqiang Zhao, Jingyu Wang, Liming Liu, Enqi Du, Enqi Du   +11 more
doaj   +1 more source